|
WO2017223422A1
|
|
Combination therapies
|
|
US2019135833A1
|
|
Heterocyclic compounds and uses thereof
|
|
WO2017161116A1
|
|
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
|
WO2017048702A1
|
|
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
|
US2017029433A1
|
|
Transfer hydrogenation of cyclopamine analogs
|
|
AU2015258280A1
|
|
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
|
WO2016054491A1
|
|
Heterocyclic compounds and uses thereof
|
|
WO2015179369A1
|
|
Treatment of pulmonary or respiratory diseases by inhalation administration of pi3 kinase inhibitors
|
|
WO2015168079A1
|
|
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
|
US2015320754A1
|
|
Combination therapies
|
|
WO2015160975A2
|
|
Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
|
|
AU2015231413A1
|
|
Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
|
|
US2016244452A1
|
|
Heterocyclic compounds and uses thereof
|
|
CN105793255A
|
|
Heterocyclic compounds and uses thereof
|
|
US2016222016A1
|
|
Heterocyclic compounds and uses thereof
|
|
US2015025012A1
|
|
Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
|
|
US2015099738A1
|
|
Isoxazolines as inhibitors of fatty acid amide hydrolase
|
|
US2016113932A1
|
|
Treatment of cancers using pi3 kinase isoform modulators
|
|
WO2014151386A1
|
|
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
US2014275135A1
|
|
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
